In a study involving more than 13,000 participants in the U.S., several messaging strategies were shown to move the ...
The EVEREST-2 study reported the first complete response to CAR-T cell therapy in a non-small cell lung cancer patient.
In a major shift for how mental health conditions might be treated, the US Food and Drug Administration (FDA) has approved ...
Chimeric antigen receptor natural killer (CAR-NK) cell therapy is emerging as a promising next-generation immunotherapy with ...
The combination therapy, referred to as DAGO+m, yielded a 91% overall response rate and a promising 2-year overall survival ...
Silica nanomaterial cuts immunotherapy costs while boosting cancer treatment efficacy by nearly 70% in animal studies.
The Global Vagus Nerve Stimulation Market Size projected to grow at a CAGR of 10.50% from 2024 to 2031, according to a new ...
Tai chi may help older adults manage chronic insomnia long-term. Learn how this mind-body exercise compares with CBT-I.
After a lengthy downturn, the biotech industry finally gathered momentum in 2025. Key readouts in obesity, infectious disease ...
As 2026 begins, a slate of high-stakes clinical readouts—from a pivotal study of Novartis’ cardiovascular candidate ...
SynuSight Biotech has licensed 18F-FD4 to XingImaging and to ABLi Therapeutics to evaluate alpha-synuclein clearance from the brain in response to risvodetinib treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback